from Tongji Hospital in China reported the efficacy of dual antigen-specific CAR T therapy, including one case of PCNSL and four cases of SCNSL that received CD19-CAR and CD22-CAR treatment (CD22 is another pan-B cell target that could enhance the treatment potency in case of CD19 antigen loss) (80). This evidence concerns the gene CD19 and primary central nervous system lymphoma.